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Primary biliary cirrhosis (PBC) is associated with immune-mediated dermatologic disorders. The association of PBC with
erythema nodosum (EN) seems rare. We report two females (42 and 44 years old) with low-grade fever, arthralgias, and elevated
cholestatic enzymes in the ﬁrst and fatigue in the second. Patients were also suﬀering from typical EN lesions characterized by
multiple erythematous, painful nodules over the anterior portions of their lower extremities. Clinical and extensive laboratory
work up excluded all known EN causes. PBC diagnosis was established according to the cholestatic biochemical proﬁle, anti-
mitochondrial antibodies (AMA) positivity and liver histology (ﬁrst), and AMA and antinuclear (ANA) PBC-speciﬁc antibodies
(second). Our report may suggest that PBC could be kept in mind in EN patients of unknown aetiology and particularly, when
middle-aged female patients are aﬀected. In such cases a thorough evaluation for AMA and/or ANA PBC-speciﬁc antibodies could
be helpful to achieve a correct and timely diagnosis.
1.Introduction
Erythema nodosum (EN) is the most common form of pan-
iculitis. It is a cutaneous reaction pattern characterized clin-
ically by the presence of erythematous tender nodules and
raised plaques. They tend to be symmetrical in distribution
and are usually located bilaterally on the lower extremities,
particularly on the anterior tibial surface, although they may
also involve the ankles, the lower parts of the thighs, and
the forearms [1–4]. Although EN usually has no speciﬁc
documented cause, it is imperative to investigate possible
triggers. Among them, streptococcal infections, tuberculosis,
inﬂammatory bowel disease (IBD), drug reactions, infective
endocarditis, and sarcoidosis are the most common causes in
children and adults [1–4].
Primary biliary cirrhosis (PBC) is an autoimmune
cholestatic liver disease, which aﬀects mainly middle-aged
women and is characterized by a progressive immune
mediated inﬂammatory destruction of the small intrahepatic
bile ducts with portal inﬂammation leading to cirrhosis and
subsequentliverfailure[5,6].Thediagnostichallmarkofthe
disease is the detection of antibodies reactive to mitochon-
dria antigens (AMA) [7–9], though several other autoanti-
bodies have been detected either disease-speciﬁc or not [7,
10–13]. The disease is frequently associated with a variety of
extrahepatic autoimmune or immune-mediated conditions,
including Sjogren’s syndrome, Hashimoto’s thyroiditis, scle-
roderma, Henoch-Schonlein purpura, and antiphospholipid
syndrome [6, 14–16]. However, so far the association of PBC
with EN seems to be extremely rare. Indeed, to the best of
our knowledge, only one case of PBC associated with EN
h a sb e e nr e p o r t e di nt h eE n g l i s hl i t e r a t u r e[ 17]. Herein,
we report two cases of early PBC associated with EN and
discuss the potential relationship among these conditions.
Both patients gave oral and written consent for the study.
2.CaseReports
2.1. Patient 1. A 42-year-old woman was admitted because
oflow-gradefever,arthralgiasandpainfulrednodulesonher2 Gastroenterology Research and Practice
legsduring thelasttendays.Herfamilyandpasthistorywere
unrevealing. Physical examination revealed palpable liver
and multiple bilateral tender erythematous nodules on her
lower extremities typical of EN. Abnormal laboratory tests
were as follows: haemoglobin 10.5g/dL, platelets 665000/μL,
erythrocyte sedimentation rate (ESR 99mm/h), aspartate
aminotransferase (AST) 45U/L (upper normal limit, UNL:
40U/L), alanine aminotransferase (ALT) 83U/L (UNL:
40U/L), gamma-glutamyl transpeptidase (γ-GT) 515U/L
(UNL: 37U/L) and alkaline phosphatase (ALP) 480U/L
(UNL:124U/L),andserumimmunoglobulinM(IgM)levels
385mg/dL (UNL: 200 mg/dL). Ultrasound of the upper
abdomen, chest X-ray, and ECG were normal. Clinical
and extensive laboratory examinations using conventional
and molecular techniques [18] ruled out known causes of
EN like IBD, sarcoidosis, and several infectious diseases
including streptococcal infections, hepatitis B, hepatitis C
and human immunodeﬁciency virus, herpes simplex virus,
cytomegalovirus, adenovirus, Echo and Coxsackie viruses,
Epstein-bar virus and brucellosis, leptospirosis, or tubercu-
losis.
However, liver autoimmune serology tests revealed
positive results for antinuclear antibodies by indirect
immunoﬂuorescence (IIF) on HEp2 cells (ANA: 1/160;
positive titre >1/40) with multiple nuclear dot (MND)
pattern and AMA: 1/160 by IIF on in-house rat multiorgan
substrate panel that included kidney, liver, and stomach
usingstandardprotocols(positive titre>1/20) [7,11,19,20].
The AMA were also detected by an enhanced performance
M2 IgG-isotype-speciﬁc ELISA (45 Units; UNL: 20 Units)
accordingtothemanufacturer’sinstructions(ELISA;Quanta
Lite, INOVA Diagnostics, San Diego, CA) and blotting [7–
9]. A complete investigation for other organ- and non-
organ-speciﬁc autoantibodies as anti-thyroid antibodies,
anti-dsDNA, anti-Ro, anti-La, anti-Sm, anti-sp100, and
anti-gp210 autoantibodies was unrevealing. A liver biopsy
was consistent with stage I of PBC according to Ludwig’s
classiﬁcation. A diagnosis of early PBC associated with
EN was then made based on the cholestatic biochemical
proﬁle, the detection of AMA, elevated IgM levels and the
liver histology. The patient was treated for both PBC and
EN with prednisolone (15mg/day with gradual tapering)
and ursodeoxycholic acid (13.5mg/kg/day). She gradually
responded and after 3 months she had normal liver function
tests (LFTs), she was out of corticosteroids use, and had no
symptoms. During the last follow-up she was still in good
health with normal LFTs and free of symptoms (only under
ursodeoxycholic acid).
2.2. Patient 2. A 44-year-old woman was admitted due
to fatigue and a history of multiple erythematous, tender
nodules over the anterior portions of her lower extremities
of 2 years duration characterized by spontaneous remissions
and exacerbations. Her family and past medical history
were unremarkable. Physical examination revealed only the
painful cutaneous lesions in the lower extremities typical
of EN. Laboratory data showed only a slight elevation of
ESR (33mm/h). As in case 1, after the exclusion of common
causes of EN the patient was investigated for autoimmune
serology markers. She was proved positive by IIF for ANA
of MND pattern (titre: 1/80) and AMA (1/160). Further
testing for ANA-PBC-speciﬁc antibodies and AMA was done
by molecularly based assays, namely, IgG-speciﬁc ELISAs
(INOVA Diagnostics, San Diego, CA), which proved also
positive for anti-sp100 (55.3 Units; UNL: 20 Units) and M2
IgG-isotype speciﬁc AMA (92 Units), respectively.
Due to the absence of elevated LFTs liver biopsy consid-
ered anethical and a diagnosis of subclinical PBC was made
based on the sex and the middle age of the patient along with
the stable positive AMA and ANA-PBC-speciﬁc antibodies.
Treatment with low dose of nonsteroidal anti-inﬂammatory
drugs was initiated with gradual improvement. Of note,
there was not any new relapse episode during the follow-
up (so far 30 months) though ANA-PBC-speciﬁc (anti-
sp100) antibodies and AMA have remained high positive
with ﬂuctuating titres during the same period. Indeed, four
investigations of 6-month intervals during the follow-up
period showed the following positive titres of anti-sp100
(ANA-PBC-speciﬁc antibodies; 37, 21, 58 and 69 Units)
and anti-M2 IgG antibodies (AMA; 80, 65.6, 98.5 and 89.4
Units), although thecholestatic enzymes werewithin normal
limits.
3. Discussion
We report here two patients presented with typical features
of EN and early PBC. To the best of our knowledge, there
has been only one publication in the English literature
describing this association [17]. PBC is an autoimmune liver
disease characterized by the occurrence of AMA (almost
pathognomonic laboratory diagnostic marker) and an asso-
ciationwithseveralotherautoimmuneorimmune-mediated
conditions [6, 14–16, 21]. Its diagnosis is often based on a
combination of characteristic symptoms including pruritus
and profound fatigue though asymptomatic cases at the
time of diagnosis are not infrequent, cholestatic liver enzyme
disturbances, positive titre of AMA, and characteristic liver
biopsy [6, 21].
EN is a common and almost challenging condition in
clinical practice. It aﬀects frequently young female patients
and the most direct and indirect evidence support the
involvement of a type IV delayed hypersensitivity response
to numerous and diﬀerent antigens for its pathogenesis.
As a result, EN has aetiologically been associated with an
extensive and heterogeneous group of diseases depending on
the population characteristics and the geographic location
[1]. For instance, streptococcal infections are the most
common identiﬁable aetiology, especially in children, while
tuberculosis has been found to be the most common
association in areas where the disease is endemic. Drug and
hormonal reactions, IBD, and granulomatous diseases, such
as sarcoidosis, tuberculosis, and granulomatous colitis have
also been reported in common among adults. As actually
from the pathophysiological perspective, PBC belongs to the
granulomatous diseases, its potential association with EN
appears rationale and attractive. Nevertheless, even after an
extensive investigation no underlying cause is identiﬁed in
almost 60% of EN cases [1].Gastroenterology Research and Practice 3
A number of skin conditions have been associated with
PBC. A recent case-control study of 49 patients with PBC
revealed that 88% of patients also had dermatologic symp-
toms and, in nearly 40% of these cases, the dermatologic
symptom led to the eventual diagnosis of PBC [22]. This
seems to be also the case in our patients, where EN was the
ﬁrst major symptom of their underlying early PBC.
In the two cases described in this paper, the diagnosis
of PBC is supported by the presence of AMA- and PBC-
speciﬁc ANA [7, 8, 11, 12]. Liver biopsy was performed in
one of them and liver histology was consistent with early
PBC (stage I). Clinical and extensive laboratory work-up
excluded sarcoidosis and other causes of EN. Of note, LFTs
were within normal limits in one patient and therefore, she
denied a liver biopsy. However, the stable presence of AMA
and ANA-PBC-speciﬁc antibodies during follow-up rather
excluded false positive serology during the acute setting of
EN. In addition, it is well known from the literature that
an isolated AMA positive test is indicative of early PBC
and that silent disease eventually becomes clinically and
biochemically evident up to 18 years after the ﬁrst AMA
screening [23, 24]. Our report demonstrated that early PBC
can be the correct diagnosis in female patients presenting
with EN after the exclusion of other common causes. The
latter could be the case even when LFTs are within normal
limits.
Conclusively, since most clinicians do not consider PBC
in the diﬀerential diagnosis of EN, our report indicates that
from the clinical point of view, PBC could be considered
in patients with EN of unknown aetiology and particularly,
when female patients of middle age are aﬀected irrespective
of the presence or absence of elevated cholestatic enzymes.
In such cases a thorough evaluation for the detection of
AMA- and/or ANA PBC-speciﬁc antibodies could be helpful
to achieve a correct and timely diagnosis. On the other
hand, it would be interesting in the future to determine the
prevalenceofthisassociationinlargecohortsofPBCpatients
and assess whether the prognosis and outcome of the disease
in these cases are diﬀerent compared to those PBC patients
without associated EN.
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